Cerevel reports positive data from Phase III Parkinson’s treatment trial
Tavapadon was well tolerated in the trial and aligned with the safety profile in previous clinical studies.
19 April 2024
19 April 2024
Tavapadon was well tolerated in the trial and aligned with the safety profile in previous clinical studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.